First-Line Treatment for Metastatic TNBC: Inside the ASCENT-03 Trial | Dr. Alissa Huston, University of Rochester

Podcast: Patient from Hell · Manta Cares

Opublikowano: 2026-10-07

This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From antibody drug conjugates and small molecules to cell therapy-based approaches, our portfolio and pipeline assets are creating new possibilities for people with cancer. UPDATE SINCE RECORDING JANUARY 2026. Since this recorded conversation, the FDA has acted on the data discussed in this episode. On May 22, 2026, Datopotamab Deruxtecan was approved for first-line...